Emerging Med Tech Market Update

1. Emerging Med Tech Market Update May 9, 2011 CONFIDENTIAL

2. Agenda • M&A Market Overview • IPO Market Overview

3. 1. M&A Market Overview

4. Med Tech M&A Environment: Increasingly Bifurcated World

5. Selected Med Tech M&A Transactions: 2009 – 2011YTD A fraction of Med Tech companies wishing to sell were able to consummate M&A transactions since 2008 market meltdown • BioControl and CardioMEMS were staged deals, which included an option to acquire the company. • Large-cap companies include those with over $10 billion in market cap. • Mid-cap companies includes those with market caps less than $10 billion but greater than $1 billion.

6. Private Med Tech Companies: “Buying Time”

7. 2. IPO Market Overview

8. Med Tech IPO Market Evolution PRE-MARKET MELTDOWN POST-MARKET MELTDOWN $200 mm Revenue $100 mm Revenue $50 mm Revenue $30 mm Revenue FDA Approval $0 mm Revenue Pre-Approval 18 month gap 18 month gap 16 month gap 2000-2002 2004-2008 2009 2011 Q4 ’11 – 1H ’12? 1995-1997

9. Med Tech IPO Market Trends • We anticipate a very orderly reopening of the Med Tech IPO market with more mature companies leading the pack • First wave of IPOs post-market meltdown • Mature businesses with $100-400 million revenue • Profitable (in most cases) • Opportunistic issuers driven by shareholder liquidity objectives • Often financial sponsor-backed vs. venture-backed • Typically some selling shareholder component as part of IPO to add size • Gradually expect lowering of “stage of development” bar to allow for return of “Traditional Med Tech IPO” defined as: • Single product or technology platform company • Modest profitability or unprofitable • Venture-backed • $75-100 million IPOs with post-money IPO valuations of $275 million+ • Keys to reopening of broader emerging growth Med Tech IPO market: • Positive investor experiences with recent Med Tech IPOs • Track record of IPO price being lowest cost point of entry to mitigate “we can buy it later cheaper” mentality • Existing public Med Tech companies trading at richer valuations, so relative risk / return assessment makes IPO comparison attractive • Valuations of public Med Tech companies returning to historical levels to support earlier stage IPOs

10. RECENTLY NORMAL Stage Set for Improved Valuations of Public Med Tech The lack of an IPO market to replenish the existing pool of public emerging growth Med Tech companies combined with steady M&A volume (reducing that pool of companies) will lead to same investment dollars chasing fewer companies… Privates Steady M&A Volume Existing PublicMed Tech Companies 15+ IPOs / year Acquisitions Privates RECENT ACQUISITIONS Shrinking Pool of Existing Public Med Tech Companies AMO AMS AGA Medical Aspect Medical ATS Medical BioSphere Medical ev3 HealthTronics I-Flow Micrus Osteotech SenoRx Somanetics Synthes TomoTherapy VNUS Medical NO IPOs …which should lead to existing public Med Tech universe appreciating in volume due to supply / demand dynamics, making those companies look more expensive and opening door for appropriately priced IPOs Source: FactSet.

11. ATRICURE CARDIOVASCULAR SYSTEMS INC MAKO SURGICAL Existing Med Tech Universe Starting to Run ATRC+167% (Since 6/1/10) Market Cap: $201mm Market Cap: $175mm CSII+126% (Since 6/1/10) NASDAQ +27% (Since 6/1/10) NASDAQ +27% (Since 6/1/10) MAKO+153% (Since 10/1/10) Market Cap: $827mm NASDAQ +19% (Since 10/1/10) Source: FactSet.